Stock Track | CareDx Stock Soars 10% on Robust Q3 Results and Upbeat Outlook

Stock Track11-05

Shares of CareDx Inc (NASDAQ: CDNA) surged over 10% in pre-market trading on November 5, 2024, after the company reported better-than-expected financial results for the third quarter ended September 30, 2024, and raised its full-year revenue guidance.

The molecular diagnostics company, which specializes in transplant patient care, reported a 23.4% year-over-year increase in revenue to $82.88 million, surpassing analyst estimates of $80.53 million. The strong revenue growth was driven by a 27% increase in testing services revenue and a 20% rise in patient and digital solutions revenue.

Additionally, CareDx reported adjusted earnings per share (EPS) of $0.14, significantly higher than the consensus estimate of $0.01 and a significant improvement from the loss of $0.18 per share reported in the same quarter last year. The company's gross margin also improved by 240 basis points to 69%, reflecting increased operational efficiency and profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162955353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162955353","market":"us","top_or_hot":-1,"title":"Stock Track | CareDx Stock Soars 10% on Robust Q3 Results and Upbeat Outlook","media":"Stock Track","content":"<p>Shares of CareDx Inc (NASDAQ: CDNA) surged over 10% in pre-market trading on November 5, 2024, after the company reported better-than-expected financial results for the third quarter ended September 30, 2024, and raised its full-year revenue guidance.</p>\n\n<p>The molecular diagnostics company, which specializes in transplant patient care, reported a 23.4% year-over-year increase in revenue to $82.88 million, surpassing analyst estimates of $80.53 million. The strong revenue growth was driven by a 27% increase in testing services revenue and a 20% rise in patient and digital solutions revenue.</p>\n\n<p>Additionally, CareDx reported adjusted earnings per share (EPS) of $0.14, significantly higher than the consensus estimate of $0.01 and a significant improvement from the loss of $0.18 per share reported in the same quarter last year. The company's gross margin also improved by 240 basis points to 69%, reflecting increased operational efficiency and profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CareDx Stock Soars 10% on Robust Q3 Results and Upbeat Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CareDx Stock Soars 10% on Robust Q3 Results and Upbeat Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-05 20:56 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of CareDx Inc (NASDAQ: CDNA) surged over 10% in pre-market trading on November 5, 2024, after the company reported better-than-expected financial results for the third quarter ended September ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"","article_id":"1162955353","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162955353","pubTimestamp":1730811403,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CareDx Inc  surged over 10% in pre-market trading on November 5, 2024, after the company reported better-than-expected financial results for the third quarter ended September 30, 2024, and raised its full-year revenue guidance.The molecular diagnostics company, which specializes in transplant patient care, reported a 23.4% year-over-year increase in revenue to $82.88 million, surpassing analyst estimates of $80.53 million. The strong revenue growth was driven by a 27% increase in testi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx"},"translate_title":"股票跟踪CareDx股价因强劲的第三季度业绩和乐观的前景而飙升10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1},"content_text":"Shares of CareDx Inc (NASDAQ: CDNA) surged over 10% in pre-market trading on November 5, 2024, after the company reported better-than-expected financial results for the third quarter ended September 30, 2024, and raised its full-year revenue guidance.\nThe molecular diagnostics company, which specializes in transplant patient care, reported a 23.4% year-over-year increase in revenue to $82.88 million, surpassing analyst estimates of $80.53 million. The strong revenue growth was driven by a 27% increase in testing services revenue and a 20% rise in patient and digital solutions revenue.\nAdditionally, CareDx reported adjusted earnings per share (EPS) of $0.14, significantly higher than the consensus estimate of $0.01 and a significant improvement from the loss of $0.18 per share reported in the same quarter last year. The company's gross margin also improved by 240 basis points to 69%, reflecting increased operational efficiency and profitability.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162955353"}